Major Shareholders Register to Sell Over $3.8 Billion in Class A Common Stock
MDLN sits 19% above its 52-week low of $38.
Summary
Medline Inc.'s major shareholders, including Blackstone, Carlyle, and H&F, have registered to sell up to 86.25 million shares of Class A common stock, valued at approximately $3.89 billion based on the current stock price, in a secondary offering from which the company will receive no proceeds.
Key Events · Financing and Capital Events · MDLN
-
Secondary Offering Registered
Selling stockholders are registering to sell up to 86.25 million shares of Class A common stock, including an option for underwriters to purchase additional shares.
-
No Proceeds to Company
Medline Inc. will not receive any funds from this offering, as it is a sale by existing shareholders.
-
Significant Shareholder Liquidation
Major institutional investors, including Blackstone, Carlyle, and H&F, are among the selling stockholders.
-
Lock-up Release
The offering is facilitated by the release of lock-up restrictions from the company's IPO in December 2025.
Analysis · MDLN · Industrial Applications And Services
This S-1 filing indicates a significant secondary offering by existing shareholders, including major institutional investors like Blackstone, Carlyle, and H&F, who are registering to sell a substantial portion of their holdings. While the company itself will not receive any proceeds from this sale, the offering represents a large increase in the public float (approximately 6.45% of the current market capitalization) and could create downward pressure on the stock price. The shares are being registered for sale at a time when the last reported closing price in the filing ($48.89 on February 26, 2026) was above the current market price ($45.07). The release of lock-up restrictions from the December 2025 IPO for these shares facilitates this sale.
At the time of this filing, MDLN was trading at $45.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $60.2B. The 52-week trading range was $38.00 to $50.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.